Gene Solutions unveiled AI-driven cancer blood tests at ESMO Asia, showing early detection and recurrence detection ahead of imaging.

Gene Solutions showcased AI-powered liquid biopsy and multi-omics advances at the 2025 ESMO Asia Congress in Singapore, highlighting SPOT-MAS, a blood test for multicancer early detection with high sensitivity and specificity in real-world studies across six Asian countries involving over 12,000 people. The K-TRACK ctDNA-MRD assay detected cancer recurrence up to 14 months earlier than imaging, while the K-4CARE platform improved precision in complex cases like cancer of unknown primary. The company reported two Best Poster Awards among seven presented abstracts, expanded its presence across India, Turkey, Taiwan, Hong Kong, and Mainland China, and advanced large-scale studies on early detection and treatment monitoring, aligning with ESMO’s guidelines on robust, fair AI biomarkers.